作者: Jen-Fu Hsu , Mei-Yin Lai , Chiang-Wen Lee , Shih-Ming Chu , I-Hsyuan Wu
DOI: 10.1186/S12879-018-3100-2
关键词:
摘要: Invasive candidiasis differs greatly between children and neonates. We aimed to investigate the different therapeutic approaches their effects on treatment outcomes of these two groups. Episodes neonatal invasive were compared with non-neonatal pediatric episodes during a 12-year cohort study. Clinical isolates documented by matrix-assisted laser desorption/ionization-time flight mass spectrometry DNA sequencing, antifungal susceptibility testing was performed. A total 342 (113 229 episodes) in 281 patients (96 neonates 185 children) identified. Candida albicans most common pathogen causing (47.8% vs. 44.1%). The profiles not significantly children. More received amphotericin B as therapy, whereas more fluconazole or caspofungin. Compared children, had longer duration fungemia, higher rates septic shock (34.5% 21.8%; P = 0.013), sepsis-attributable mortality (28.3% 17.5%; P = 0.024) in-hospital (42.7% 25.4%; P = 0.004) than Independent risk factors for failure (odds ration [OR] 16.01; 95% confidence interval [CI] 7.64–33.56; P < 0.001), delayed removal intravenous catheter (OR 6.78; CI 2.80–17.41; renal 5.38; 1.99–14.57; P = 0.001), breakthrough 2.99; 1.04–8.67; P = 0.043). Neonatal has worse candidiasis. Neonatologists pediatricians must consider age-specific differences when developing prevention guidelines, interpreting studies other age